Abilify Potential Safety Issues Flagged By FDA In Quarterly AERS Review
Executive Summary
FDA is evaluating a number of possible safety signals related to Bristol-Myers Squibb's antipsychotic Abilify (aripiprazole), according to a 1report posted to the agency's Web site Feb. 4